Treatment for Arteriovenous Fistula
This study is evaluating whether a new type of catheter may help treat blood vessels in the upper arm.
See full descriptionAbout the trial for Arteriovenous Fistula
Treatment Groups
This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Eligibility
This trial is for patients born any sex aged 18 and older. There are 9 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Treatment will improve 2 primary outcomes, 10 secondary outcomes, and 1 other outcome in patients with Arteriovenous Fistula. Measurement will happen over the course of 30 days.
Patient Q & A Section
How many people get arteriovenous fistula a year in the United States?
About 6.9 per 100,000 US citizens will have a fistula in 10 years. The incidence was higher in Hispanic or Latino and lower in African Americans. Male sex, advanced age, and hepatitis c virus (HCV) positivity were statistically significant risk factors independently associated with fistula. Fistulas are more common at older ages when people get dialysis for chronic renal failure, whereas AVFs are more common in younger individuals with a history of cancer radiation or surgery and when patients start outpatient hemodialysis as opposed to inpatient hemodialysis.
What are the signs of arteriovenous fistula?
The presence of peripheral edema is a key diagnostic criterion in patients with the clinical suspicion of AV fistula. The presence of an indwelling venous catheter can also be an important diagnostic clue.
What are common treatments for arteriovenous fistula?
The most common treatment for an arteriovenous fistula is the surgical correction of an obstruction, often performed in a minimally invasive fashion with use of the autogenous vein as a vascular graft. An anastomosis is commonly placed to correct fistulas caused by hemodialysis access. A vascular graft can be placed to correct a malperfused fistula caused by atherosclerosis. More than 90% of all vascular access placements in hemodialysis patients are performed with the use of AVGs as a vascular graft.
Can arteriovenous fistula be cured?
Data from a recent study demonstrated satisfactory results regarding a variety of fistula indications and the absence of complications or recurrences. We did not observe a progressive narrowing of the fistula between the years analyzed.
What is arteriovenous fistula?
A fistular access can be built in about 74% patients, with a low-mortality rate (less than 2% of bypass procedures are required) if correct use is made of the bypass technique. The risk of developing an access stenosis is low with this simple technique, and the technique should be used routinely in all patients undergoing vascular surgery. A single access can be used on average every second day for an average of about 2 weeks.
What causes arteriovenous fistula?
These data show no association between the presence of an arteriovenous fistula and its cause. There does not appear to be some sort of "artery to vein fistula syndrome." The patient's underlying vascular or connective tissue disorders are thought to be responsible for the development of an arteriovenous fistula.
What is the average age someone gets arteriovenous fistula?
It is important to note, however, that when a person uses a CVC, the cannula may slowly pull through the tissue of the arterial wall, and the blood vessels and nerves of the body can continue to communicate as new blood vessels grow and expand in size. This can occur in as little as one week after a successful implantation. Consequently, the actual vascular access placement could be occurring after 2 to 3 months.
What are the latest developments in treatment for therapeutic use?
These recent advances in the field of EVTs and a new, biocompatible material are definitely expanding the choice of EVT options which will facilitate patients in selecting their best options. The new EVT devices seem to combine the ideal of biocompatibility with mechanical stability and the low cost of conventional EVTs. While most data on EVT durability are related to EVTs implanted by surgical methods, clinical trials, with EVTs implanted in percutaneous fenestrations, are expanding their patient numbers exponentially over time and they seem to provide satisfactory and acceptable midterm patency rates.
What is the primary cause of arteriovenous fistula?
We observed a high incidence of AVF with a primary malignancy or traumatic origin, but a relatively small incidence of secondary AVF following radiotherapy of hematologic cancers.
What is the latest research for arteriovenous fistula?
Using the latest scientific evidence and data to guide their treatment, surgeons are making the decision to use arteriovenous fistula (A/V) for many end-stage kidney disease patients. In some cases, this technique can be lifesaving for renal patients. In other cases, patients can live longer and maybe even healthier lives.
Have there been any new discoveries for treating arteriovenous fistula?
Treatment options for AVF are extremely limited. No new treatments have been specifically validated in clinical trials. However, there have been new advances in other medical disciplines which may influence the management of AVF.
Is treatment safe for people?
For AVF treatment in older patients, as many as 80% have no long-term treatment complications. This cohort of AVF-treated older patients can be expected to live longer and at a higher level of functioning, given appropriate treatment, care, and access to care.